FAST-EU: Enhancing Efficiency in European Clinical Trials

March 25, 2026 by Rubin Joshi

How FAST‑EU reshapes EU clinical trial approvals

The Facilitating and Accelerating Strategic Clinical Trials in the EU initiative (FAST-EU), launched this year, sets a new benchmark for the European clinical trial landscape. By offering a coordinated <70-day assessment timeline for multi-national clinical trials, the initiative is a clear signal of Europe’s strengthened position in cell and gene therapy.

Member states, not the European Medicines Agency (EMA), drive the accelerated timeline, coordinating scientific and ethics reviews in parallel while maintaining high standards. For sponsors of advanced therapy medicinal products (ATMPs), gene therapies, and innovative treatments, FAST-EU unlocks faster trial startups, boosts sponsor confidence and reduces regulatory uncertainty.

FAST-EU vs. CTR: Accelerated Timelines
Under the previous Clinical Trials Regulation (CTR) and Clinical Trials Information System (CTIS), multinational trial approvals could take up to 106 days, with multiple phases and requests for additional information from member states often causing delays. The FAST-EU model delivers:

• Simultaneous Validation and Assessment: Validation, Part I, and Part II processes now start on the day of application
• Faster Milestones: Consolidated workflows accelerate draft reporting and decisions
• Fewer RFI Rounds: Only one Request for Information (RFI) per phase/member state, emphasizing robust and compliant initial submissions

Key assessment milestones include submission (Day 0), initial validation (Day 7), draft reports (Day 28), consolidated review (Day 42), and final assessment by Day 70. Substantial preparation is necessary, as sponsors must respond to RFIs within 12 days.

Strategic Readiness for FAST-EU
Sponsors seeking to benefit from FAST-EU should focus on:

• Comprehensive Dossiers: Submit aligned documentation including protocols, Investigator’s Brochure, IMPD, and detailed chemistry, manufacturing, and controls (CMC) sections. Advanced therapy and gene therapy sponsors must adhere to current EMA guidelines.
• Finalized CMC Strategies: Complete and harmonized CMC data packages. Delays or inconsistencies cannot be accommodated under FAST-EU’s strict timelines.
• Agile Cross-Functional Teams: Ensure regulatory, clinical, CMC, and legal stakeholders can address queries swiftly.

FAST-EU Selection and Eligibility
FAST-EU operates as a pilot, permitting two trials per month. Multinational, fully compliant applications are prioritized, especially those with broad member state engagement, experienced Reporting Member States (RMS), and high public or medical value. Submissions require a detailed Letter of Intention and early engagement with authorities.

Integrating With the EU Biotech Act
FAST-EU aligns with the proposed EU Biotech Act, which aims to permanently shorten clinical trial timelines and simplify evaluation. Mastery of the FAST-EU model positions sponsors for success as these accelerated pathways become standard.

Key Preparation Steps

To ensure compliance and maximize efficiency:

• Conduct comprehensive dossier evaluations for completeness and quality
• Assemble cross-functional teams for rapid, informed regulatory responses
• Complete CMC documentation consistent with EMA and member state requirements
• Engage Aldevron for regulatory support to mitigate risk and deliver efficient submissions

Aldevron’s Role in Regulatory Excellence
FAST-EU is redefining clinical trial processes in Europe, offering reduced approval timelines and stronger market positioning for innovative therapy sponsors. Success demands operational rigor and proactive regulatory strategy. Aldevron provides comprehensive regulatory support, empowering sponsors to succeed within the accelerated FAST-EU framework:

• Thorough documentation reviews for regulatory alignment and completeness
• Structuring CMC data packages for ATMPs and gene therapy programs
• Technical guidance and multidisciplinary coordination to expedite responses to regulatory authorities

By adopting proven best practices and strategic partnerships, sponsors can secure a confident pathway through the next era of European clinical trial development. With Aldevron’s experience and systems, sponsors could gain a significant advantage, meeting the rigorous expectations of FAST-EU while maximizing trial readiness and regulatory compliance.

• Have questions on this topic? Contact Us
• Learn more about the FAST-EU initiative
• Explore Aldevron’s regulatory solutions
• Have an idea for a topic? Let us know!

Subscribe to our blog